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PURPOSE. We determine whether intravitreal angiopoietin-1 combined with the short coiled-
coil domain of cartilage oligomeric matrix protein by adeno-associated viral serotype 2
(AAV2.COMP-Ang1) delivery following the onset of vascular damage could rescue or repair
damaged vascular beds and attenuate neuronal atrophy and dysfunction in the retinas of aged
diabetic mice.
METHODS. AAV2.COMP-Ang1 was bilaterally injected into the vitreous of 6-month-old male
Ins2Akita mice. Age-matched controls consisted of uninjected C57BL/6J and Ins2Akita males,
and of Ins2Akita males injected with PBS or AAV2.REPORTER (AcGFP or LacZ). Retinal
thickness and visual acuity were measured in vivo at baseline and at the 10.5-month endpoint.
Ex vivo vascular parameters were measured from retinal flat mounts, and Western blot was
used to detect protein expression.
RESULTS. All three Ins2Akita control groups showed significantly increased deep vascular
density at 10.5 months compared to uninjected C57BL/6J retinas (as measured by vessel area,
length, lacunarity, and number of junctions). In contrast, deep microvascular density of
Ins2Akita retinas treated with AAV2.COMP-Ang1 was more similar to uninjected C57BL/6J
retinas for all parameters. However, no significant improvement in retinal thinning or diabetic
retinopathy–associated visual loss was found in treated diabetic retinas.
CONCLUSIONS. Deep retinal microvasculature of diabetic Ins2Akita eyes shows late stage changes
consistent with disorganized vascular proliferation. We show that intravitreally injected
AAV2.COMP-Ang1 blocks this increase in deep microvascularity, even when administered
subsequent to development of the first detectable vascular defects. However, improving
vascular normalization did not attenuate neuroretinal degeneration or loss of visual acuity.
Therefore, additional interventions are required to address neurodegenerative changes that
are already underway.
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Diabetic retinopathy (DR) is the leading global cause ofblindness in working individuals and one of the leading
microvascular complications of diabetes.1 Clinically, nonproli-
ferative DR (NPDR) involves progressive damage of the retinal
vessels with capillary dropout. Microvascular changes include
microaneurysms, hemorrhages, and intraretinal microvascular
abnormalities (IRMAs), which are tortuous intraretinal vascular
segments. Progressive capillary dropout leads to hypoxia,
proceeded by proliferating networks of leaky neovessels that
can expand from the inner retina into the vitreous cavity – the
hallmark of proliferative DR (PDR).
Diabetic hyperglycemia is toxic to the retinal microvascu-
lature, disrupting endothelial tight junctions leading to break-
down of the blood-retinal barrier (BRB). Inflammatory
mediators (i.e., TNF-a, IL-1b, and IL-6) upregulate adhesion
molecules and growth factors (i.e., intercellular adhesion
molecule–1 [ICAM-1] and VEGF), which in turn promote
leukocyte-endothelial adhesion (54,55), a critical step in DR
pathogenesis. Diabetes likely impairs the neural retina concur-
rent with (or before) vascular defects, as declines in visual
electrophysiology can be detected in diabetic patients and
animal models even before any clinically detectable symptoms
of DR.2,3 Chronic inflammation is likely a key factor in
impairment of both the retinal microvasculature and the neural
retina.4–6
Anti-VEGF therapies, such as ranibizumab and Aflibercept,
arrest the pathologic angiogenesis of PDR, yet achieve
temporary visual improvement in only a minority (23%–34%)
of patients,7–10 and therapies targeting alternative pathways to
reverse progressive neurovascular dysfunction are needed.
Type 1 Diabetic Ins2Akita mice suffer hyperglycemia by 4 weeks
of age and show degenerative retinal changes by 6 months,
including acellular capillaries, pericyte loss, retinal thinning,
visual dysfunction, and b-wave diminution.11–14 Although no
rodent models faithfully recapitulate the vascular proliferation
seen in human PDR, recent studies have reported an increase of
Copyright 2019 The Authors
iovs.arvojournals.org j ISSN: 1552-5783 2494
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloaded from iovs.arvojournals.org on 06/12/2019
vascular density in the deep vascular plexus of aged diabetic
db/db and Ins2Akita mice,15–17 suggestive of the impaired
vascular remodelling seen in ‘‘preproliferative’’ DR marked by
IRMAs in human patients, a precursor of proliferative DR.18,19
Work in our and other laboratories suggests that Angio-
poietin1 therapy can halt nonproliferative structural and
functional changes associated with DR in mice, such as retinal
thinning, acellular capillaries, and optokinetic tracking dys-
function.13,20,21 The angiopoietins (Ang1 and Ang2) are
secreted ligands that bind to the receptor tyrosine kinase
Tie2 expressed on endothelial and hematopoietic cells.
Whereas Ang2 is a context-dependent antagonist of Ang1/
Tie2 signaling, Ang1 activation of Tie2 induces vessel survival,
quiescence, and maturation, and decreases inflammation and
leakiness in response to permeability-inducing inflammatory
agents.21,22 Our previous work has shown that sustained
intravitreal expression of angiopoietin-1 combined with the
short coiled-coil domain of cartilage oligomeric matrix protein
(COMP-Ang1) by adeno-associated viral serotype 2 (AAV2.-
COMP-Ang1) in 2-month old Ins2Akita males significantly
attenuated capillary loss, breakdown of the BRB, and
subsequent leukostasis, as well as preventing retinal thinning
and loss of visual acuity, all of which occur in untreated
Ins2Akita mice and DR patients.11–14,16,23,24
However, as progression of DR generally is well underway
before clinical diagnosis, preventive management and early
treatment is not an option for many patients. We show that
delaying AAV2.COMP-Ang1 treatment well after DR onset was
successful in preventing subsequent proliferative vascular
retinopathy of the deep plexus in aged Ins2Akita mice. Despite
this effect, delayed AAV2.COMP-Ang1 therapy did not attenu-
ate progressive thinning of the peripheral retina, suggesting
that additional nonvascular processes underlie susceptibility of
neurons to chronic hyperglycemia, particularly once retinal
thinning already is underway.
METHODS
Animals
The type 1 diabetic Ins2Akita mouse on the C57BL/6J
background was used to model DR. This animal harbors a
mutation in the insulin gene that prevents proper insulin
secretion. Heterozygous C57BL/6-Ins2Akita/J (Ins2Akita) males
and healthy C57BL/6J female mice were obtained from the
Jackson Laboratory (Sacramento, CA, USA) and crossed in our
pathogen-free animal facility. As only male Ins2Akita mice
consistently suffer diabetes, female pups were euthanized
and male pups were genotyped at weaning (additional
information in Supplementary Materials and Methods). Exper-
iments were approved by the Institutional Animal Care and Use
Committee of the University of Utah and conform to the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research.
Ins2Akita mice were randomly assigned to an experimental
treatment group: AAV2.COMP-Ang1 (carrying a 30 FLAG tag for
purification and immunodetection) or to one of three control
groups: no injection, PBS, or AAV2.REPORTER (AcGFP or
LacZ). All AAV2 constructs were driven by the CMV promoter.
Wild type (WT) littermates received no ocular treatment
(additional information provided in Supplementary Materials
and Methods). High mortality of the aging Ins2Akita population
precluded our ability to use equivalent numbers of each group
for all assays. Six-month old Ins2Akita mice were treated with
either 1 lL solution containing AAV2.COMP-Ang1, AAV2.RE-
PORTER (2.0 3 109 viral genomes [VG]) or PBS injected into
the vitreous cavity of both eyes.
In Vivo Imaging
In vivo retinal cross-sectional thickness was imaged bilaterally
with optical coherence tomography (OCT; Spectralis HRAþOCT,
Heidelberg Engineering, Heidelberg, Germany). Baseline thick-
ness was measured in 6-month-old male Ins2Akita mice before
intravitreal injections, in 10.5-month-old (62 weeks) Ins2Akita
and in age-matched WT littermates at both time points. OCT
images were manually segmented and total retinal thickness was
measured between the retinal nerve fiber layer (RNFL) and the
basement membrane (BM) by an observer blinded to the
treatment type. Four measurements corresponding to each of
the retinal quadrants were averaged across both eyes at radial
distances 0.5, 1.5, 2.5, 3.5, and 4.5 mm from the optic nerve
head. Expression of the AAV2.AcGFP control vector in Ins2Akita
mice was assessed in vivo using the FA imaging modality of the
Heidelberg Spectralis (additional information provided in
Supplementary Materials and Methods).
Immunofluorescent Labeling of Retinal Flat-
Mounts
All procedures performed ex vivo were completed on retinas
harvested at the experimental endpoint of 10.5 months (62
weeks of age). See Supplementary Material and Methods for a
detailed description of flat mount immunostaining and
preparation.
Imaging and Image Processing
Vascular Quantification (Low Resolution),310 Objec-
tive. Equivalent fluorescence parameters were set using an
EVOS FL imaging system to acquire 310 stitched images of
whole flat mounts labeled with fluorescent GS-IB4. Tiff images
were inverted and transformed to grayscale in Photoshop
(Adobe, San Jose, CA, USA) and imported into ImageJ (National
Institutes of Health [NIH], Bethesda, MD, USA) for processing.
In ImageJ, retinas were first outlined with the polygon tool, and
the thresholding tool was used to convert all pixels to binary
states by setting minimum and maximum thresholds ¼ 230
(>230¼ black, <230¼white). The total number of black and
white pixels enclosed by the polygon was calculated and vessel
density was calculated as #black/total pixels.
Deep Vascular Quantification (High Resolution), 340
Objective. Efforts were taken to minimize sampling bias of the
deep plexus as follows: Peripheral fields were manually
selected using a Zeiss LSM 800 (340 objective; Carl Zeiss
Meditec, Jena, Germany) while focusing only within the
superficial microvascular plane. After selecting each field, the
focal plane was reset to the deep vascular plexus for imaging,
and Z-stacks encompassing this layer were captured at 1 lm
intervals. Supplementary Figure S1a shows that 1 lm interval
distances are sufficient to image the deep vasculature while
preventing confounding fluorescence from adjacent GS-IB4
fluorescent vascular beds.
Eight nonoverlapping fields within the retinal periphery
(approximately 2.5 objective distances from the optic nerve)
were selected across the four retinal quadrants. Images within
each Z-stack were merged using ZEN lite (blue edition; Carl
Zeiss Meditec) and the orthogonal projections were saved as
tiff files for importing into Photoshop. A treatment-blind
observer then manually masked extravascular cell types
(infiltrating leukocytes, microglia, and macrophages) to elim-
inate this potential source of confounding GS-IB4 positive
signal. Cleaned images subsequently were processed through
AngioTool25 (Supplementary Fig. S1B; available in the public
domain at https://ccrod.cancer.gov/confluence/display/ROB2/
Home), with equivalent parameter settings (intensity and
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vessel diameter range) across the entire dataset. The eight
values representing eight separate peripheral retinal fields
were averaged for each eye. Reported statistics are for: total
vessels length, lacunarity,26 (an index describing the distribu-
tion of the sizes of gaps, or ‘‘gappiness’’ within the image),
number of vessel junctions, and vessels percentage area.
Optokinetic Tracking (OKT) for Visual Acuity
Optomotor reflex-based spatial frequency threshold tests were
conducted on awake, unrestrained mice by a treatment-na¨ıve
operator using a visuomotor behavior measuring system
(OptoMotry; CerebralMechanics, Lethbridge, AB, Canada).
Presence or absence of the stimulus tracking response was
established through repeated trials of varying direction and
spatial frequency of the stimulus. Spatial frequency of the
stimulus was stepped up or down with the staircase method to
find the behavioral threshold, corresponding to the visual
acuity for the behavior. Rotation speed (128/s) and contrast
(100%) were kept constant. WT and Ins2Akita mice underwent
OKT at the 10.5-month endpoint.
Statistical Analysis
Numerical data were calculated in Excel (Microsoft, Redmond,
WA, USA) and are presented as the mean 6 SEM. The Student’s
2-tailed t-test with a significance level of 0.05 was used to
compare differences between two groups. For analysis of
multiple groups, statistical analyses were performed with Past3
software.27 Significant differences were first tested by ANOVA
for P < 0.05, followed by Tukey’s honest significant difference
(HSD) test for pairwise comparisons of groups with unequal
sample sizes.
RESULTS
Mortality is Increased 7.8-Fold in Diabetic Mice
As expected, 6-month-old Ins2Akita males showed significantly
elevated fasting blood glucose levels (Fig. 1A) and decreased
body weights (Fig. 1B) relative to WT littermates (Glucose: WT,
149.8 6 19.8 mg/dL; Ins2Akita, 475.6 6 52.4 mg/dL; Body
Weight: WT, 35.4 6 4.25 g; Ins2Akita, 25.3 6 2.1 g). Overall
mortality rates increased sharply relative to WT littermates at
approximately 6 months of age (Fig. 1C). Total mortality by the
10.5-month endpoint was 42.2% in Ins2Akita mice, but only
5.4% in WT mice, a 7.8-fold increase. Due to the increased
fragility of aged Ins2Akita mice, we avoided procedures
requiring extended use of anesthesia on these animals.
Diabetic Retinas Maintain Long-Term Viral
Expression
Intraocular gene therapy was sustained for the duration of the
experiments. Ex vivo images of AAV2.AcGFP injected retinal
flat mounts show naked AcGFP expression consistent with in
vivo imaging (Fig. 2). In vivo and ex vivo images showed
fluorescent localization varying across retinal quadrants with
the highest fluorescence close to the injection site. Expression
of intravitreally injected AAV2.COMP-Ang1 was visualized in
eight specimens by indirect immunofluorescent localization of
FIGURE 1. Ins2Akita mice show significant progression of diabetes by 6
months, including (A) elevated fasting blood glucose levels (P <
0.0001, Student’s t-test) and (B) lower body weight (P < 0.005,
Students t-test) relative to WT littermates. (C) Ins2Akita suffered
significantly greater mortality than WT mice starting sharply at 6
months (logrank test, P¼ 0.008).
FIGURE 2. AAV2 expression is detectable 5 months after intravitreal
injection. Top: The same retina was imaged for AAV2.AcGFP expression
in vivo (left) by Spectralis FA mode, and ex vivo (right) by direct
detection with GFP wavelength filter cube. Bottom: Indirect immuno-
fluorescent detection of COMP-Ang1 using a FLAG tag in the
AAV2.COMP-Ang1 viral construct (left þ inset). FLAG signal is
undetectable in untreated retinas (right).
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the incorporated FLAG tag. No control retina exhibited FLAG-
specific fluorescent signal (Fig. 2). Considerable variability in
FLAG-immunofluorescent cell counts was found among AAV2.-
COMP-Ang1–treated eyes, presumably due to variability in
manual injections, and average number of COMP-Ang1–
expressing cells varied over 5-fold among the eight FLAG-
labeled retina. As COMP-Ang1 (and FLAG) is secreted extracel-
lularly, this signal was lower than naked AcGFP signal in the
AAV2.AcGFP injected retinas. Nevertheless, these data demon-
strated that our AAV2 reagents can be targeted to (and sustained
in) retinas following onset of DR for at least 5 months.
AAV2.COMP-Ang1 Prevents Proliferation of the
Deep Vascular Network
We first attempted to assess vascularity at the experimental
endpoint by measuring the total vascular signal in stitched310
objective images of GS-IB4-alexa488 labeled retinal flat mounts.
Surprisingly, AAV2-treated diabetic retinas appeared more
strongly labeled than those of WT and PBS-treated Ins2Akita
mice. Specifically, AAV2 expression vectors appeared to be
associated with increased numbers of GS-IB4-alexa488 labeled
monocytes/macrophages mostly confined to the superficial
vascular plexus (Fig. 3A). Using the pan-macrophage/monocyte
lineage marker Iba1, we found that approximately 85% of these
extravascular cells labeled with GS-IB4 and Iba1 in Ins2Akita
retinas previously treated with intravitreal AAV2.LacZ or
AAV2.COMP-Ang1 (Supplementary Fig. S2 and data not
shown). Increased fluorescence of AAV2-treated diabetic
retinas was confirmed by quantification of vascular signal
across groups (Fig. 3B), indicating that the presence of GS-IB4–
labeled extravascular cell types can introduce unacceptable
bias to vascular quantification.
To obtain a more objective measure of retinal vascularity
than the above low-resolution protocol, we imaged new
cohorts of endpoint retinas that were labeled with GS-IB4-
alexa647. Eight high-resolution 340 confocal Z-stacks of the
deep vascular plexus were captured approximately 2.5
objective diameters peripheral to the optic nerve and
processed through AngioTool as per previous reports.17,25,28
In contrast to the progressive capillary loss reported in studies
(including ours) of younger Ins2Akita mice,13,29 retinas of the
10.5-month-old control Ins2Akita mice demonstrated significant
increases in total length and area of microvessels, number of
FIGURE 3. Isolectin B4 flat mounts of 10.5-month-old retinas. (A) GS-IB4-FITC lectin-labeled retinal flat mounts. Clusters of nonvascular cell types
labeled by lectin are enclosed by ovals. (B) Retinas injected with AAV2 expression vectors had significantly higher intensity scores than WT or PBS-
treated Ins2Akita retinas. **P < 0.01, ***P < 0.001.
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vessel junctions, and a decrease in lacunarity compared to
untreated WT retinas (Fig. 4). Whereas all diabetic control
groups showed an expansion of vessels in the deep vascular
plexus, AAV2.Comp-Ang1–treated Ins2Akita retinas were com-
parable to WT retinas for all vascular measures, while differing
significantly from Ins2Akita control groups, suggesting that
Comp-Ang1 attenuated the diabetes-induced expansion of the
deep vascular network.
Studies of diabetic rodents and humans show that ERK1/2 is
activated in the diabetic retina, and may have a key role in
glucose-mediated inflammatory induction.30–33 Quantification
of Western blot band intensities indicated that pERK1/2
protein levels of AAV2.COMP-Ang1–treated diabetic retinas
were 41% lower than control diabetic retinas (Fig. 5A).
However, this trend was not significant when comparing
group means of WT, COMP-Ang1 Ins2Akita, and control Ins2Akita
retinas (ANOVA, P ¼ 0.23). Interestingly, levels of membrane-
bound (C-terminal) Tie2 were similar among all Ins2Akita
control retinas, and insignificantly lower (20%) than Tie2
levels in WT retinas, suggesting that AAV2.COMP-Ang1–
mediated vascular rescue was achieved without upregulating
expression of its canonical receptor (Fig. 5B).
AAV2.COMP-Ang1 Treatment Does Not Prevent
Retinal Thinning or Loss Of Visual Acuity in Six-
Month-Old Ins2Akita Mice
Baseline and endpoint retinal thickness were measured and
averaged across the four retinal quadrants at 1.5 mm
incremental radial distances peripheral to the optic nerve
head. Baseline retinal thickness of Ins2Akita retinas was
significantly thinner than WT age-matched littermate retinas
at all radial distances, and retinas of both genotypes continued
to thin with age (Fig. 6A). However, AAV2-treated mice had
expanded central retinas, tapering gradually toward the
periphery, whereas thickness of WT and PBS-treated retinas
was greatest at the 2.5 mm distance, tapering toward central
retina and periphery (Figs. 6B–D). Despite the increased
central retinal thickness, AAV2.COMP-Ang1 did not provide
any protection from peripheral retinal thinning.
Peripheral retinal ganglion cell (RGC) counts (Supplemen-
tary Fig. S3) of WT, AAV2.COMP-Ang1– and PBS-injected eyes
were significantly higher than peripheral RGC counts of
AAV2.REPORTER–injected retinas (ANOVA, P < 0.05, Fig.
7A), suggesting potential neurotoxicity of chronic exogenous
FIGURE 4. COMP-Ang1 treatment inhibits proliferative deep vascular remodeling in aged Ins2Akita retinas. (A) Representative340 confocal Z-stack
images of WT and Ins2Akita deep plexus. (B–E) Several indices of vascularity: (B) vessel length, (C) lacunarity, (D) number of vessel junctions, and (E)
vascular area indicate that between 6 and 10 months of age, the deep vascular plexus of Ins2Akita retinas is remodeled to increase vascular density
relative to age-matched WT retinas (black bars and asterisks). In contrast, AAV2.COMP-Ang1–treated retinas were statistically more similar to WT
retinas for all comparisons (red bars and asterisks). N¼ 5 (WT, NI, and PBS), N¼ 8 (Reporter), N¼ 9 (CA1) *P < 0.05, **P < 0.01, ***P < 0.005.
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reporter protein to this cell type in diabetic mice. Surprisingly,
RGC counts of WT, PBS-injected, and AAV2.COMP-Ang1–
injected retinas were not significantly different from each
other, although we observed the trend: WT > AAV2.COMP-
Ang1 > PBS.
Visual deficits arise early in DR patients and animal models,
which can be measured as a decline in visual tracking behavior.
We previously showed that Ins2Akita mice treated with
AAV2.COMP-Ang1 before DR symptoms were capable of
resisting deterioration of optokinetic visual function.13 How-
ever, consistent with the lack of rescue in retinal thickness,
delaying AAV2.COMP-Ang1 treatment until 6 months failed to
reverse or prevent further declines in visual acuity (Fig. 7B).
Average right plus left eye acuity scores of all Ins2Akita groups
were significantly below those of WT mice (P < 0.05), but did
not differ from each other.
DISCUSSION
This study highlights important functional differences in Ang1/
Tie2 signaling in the diabetic retina associated with disease
progression and age. Studying proliferative DR remains a
challenge. The rodent oxygen-induced retinopathy models
exhibit rampant retinal neovascularization and are better
correlates of retinopathy of prematurity, whereas the diabetic
Akimba mouse has significant retinal cell loss. Neither the
chronic models of Ins2Akita nor db/db have the retinal
FIGURE 5. AAV2.COMP-Ang1 treatment reduced levels of phosphory-
lated ERK1/2 in the absence of Tie2 upregulation. (A) Protein levels of
phosphorylated ERK1/2 in AAV2.COMP-Ang1 (CA1) retinas were 41%
lower than diabetic control retinas, although this trend was not
significant. (NI, no injection). (B) Retinal Tie2 receptor levels (C-
terminal Tie2) of all Ins2Akita groups were not significantly different
from each other, but showed a trend of 20% less receptor protein than
WT retinas.
FIGURE 6. Retinal thinning was not prevented or improved after delayed COMP-Ang1 treatment. (A) Considerable retinal thinning occurred
between baseline (6 months) and the experimental endpoint (10.5 months) in WT and Ins2Akita mice. However, retinal thickness of Ins2Akita mice
was below that of age-matched WT littermates at all radial distances from the optic nerve head. (B) Representative images of HRA (left) and OCT
images of all four study groups at the 10.5-month endpoint. The dashed blue line is at approximately 0.5 radial distance from the optic nerve head
(solid green line). (C) Average retinal thickness at increasing radial distances from the optic nerve head is represented by a colored line for each
group. Note that central retinas of the two AAV2-treated groups are considerably thicker than that of the PBS-injected group, whereas peripheral
retinas of all Ins2Akita groups are similar. (D) Same retinal thickness data (and color code) as in (C) but represented as bar graphs with pairwise
comparisons performed at each radial distance that showed a significant difference among the group means. AAV2.COMP-Ang1 (AAV2.CA1)
treatment did not prevent significant peripheral retinal thinning (*P < 0.05; **P < 0.01).
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neovascularization seen in human patients. However, our
confirmation that deep vascular proliferation occurs in diabetic
mice provides the opportunity to explore therapies for
normalizing proliferative remodeling in the adult diabetic
retina.15–17
DR often is well advanced in patients before diagnosis.
Therefore, it is critical to determine how therapeutic outcome
varies with treatment initiated at later stages of disease. Novel
treatments tested in rodent models are generally delivered
before disease onset and studies terminate at or near 6 months
of age before a sharp increase in diabetes-associated mortality
occurs. Our study confirmed that beyond 6 months, the deep
capillary plexus of Ins2Akita mice undergoes extensive prolif-
erative remodeling at the retinal periphery. We suggested that
this remodeling may reflect IRMAs found in human patients.
IRMAs are proliferations that occur deeper in the retina than
neovascularization and are likely a precursor to preretinal
neovascularization.18,19
We demonstrated an antiangiogenic effect of AAV2.COMP-
Ang1 in Ins2Akita retinas when delivery is initiated well after the
establishment of diabetes, subsequent to pericyte dropout,
capillary loss, and the onset of retinal thinning. Whereas early
intervention with AAV2.COMP-Ang1 (at 2 months) halted the
progression of vascular and neuronal impairment,13 treatment
at 6 months encountered an established inflammatory milieu
with ongoing neurovascular degeneration. Yet even under
these conditions, AAV2.COMP-Ang1 successfully mitigated
persistent proangiogenic activity within the deep capillary
bed, although it did not retard ongoing neuronal loss.
Body weights begin to diverge among diabetic and
nondiabetic littermates soon after weaning and Ins2Akita males
have significantly lower mass by 6 months. The fragility of aged
diabetic males makes long-term studies challenging; we found
a 7.8-fold increase in the mortality of our Ins2Akita mice relative
to WT littermates, similar to a 5- to 10-fold increase in mortality
risk for human patients with type1 diabetes.34 As the general
frailty of aged Ins2Akitas can contribute to behavioral changes
among diabetic and nondiabetic littermates, this may exagger-
ate variation in behavioral tests of retinal function, such as
OKT, which relies on the subtle head movements of subjects
during visual tracking. Therefore, although we found no
significant difference among OKT scores of control and treated
Ins2Akita mice, it is important to note that diabetes-associated
declines in behavioral responsiveness may confound the ability
to detect improvements in visual acuity.
ERK1/2 phorphorylation is required for proproliferative,
promigratory endothelial activity,35 and is upregulated in the
diabetic retinas of rodents and humans, drawing interest to its
potential as a therapeutic target for DR.20,31–33 Although Ang1/
Tie2 signaling upregulates ERK1/2 phosphorylation in vi-
tro,36,37 Ang1 supplementation was reported previously to
have the opposite effect in diabetic mouse retinas, reversing
the diabetes-associated pERK1/2 increase.20 Consistent with
this, we found a strong trend (41%) of reduced pERK1/2 levels
in diabetic retinas with AAV2.COMP-Ang1, even when treated
after DR onset. However, the low number of retinal samples
tested is a limitation of this analysis. Interestingly, levels of
membrane-bound Tie2 receptor levels remained unchanged in
AAV2.COMP-Ang1–treated diabetic retinas. As angiopoiteins
can mediate endothelial activity via direct binding and
induction of integrin pathways,38,39 exploring the role of
integrins in Ang1-mediated diabetic repair may be worthwhile.
AAV2.REPORTER and AAV2.COMP-Ang1 treatments led to
infiltration of GS-IB4–labeled extravascular cells. We found that
the panmacrophage/monocyte marker Iba1 colocalized with
the majority of extravascular GS-IB4–labeled cells, suggesting
an inflammatory identity. As AAV2 treatment also was
associated with increased central retinal thickness suggestive
of edema, we suspected that our AAV2 dosage (23 109 VG) is
at the high end for retinas with established DR. Indeed, a
previous report determined that diabetes enhances the retinal
transduction and efficacy of AAV2 vectors,40 suggesting that
viral dose should be optimized at different time points
following disease onset.
Using OCT angiography (OCTA), we recently confirmed
that 6-month old Ins2Akita mice show significantly reduced
perfusion, particularly in the deep vascular plexus.29 Even
temporary lack of motion contrast (blood flow) is undetectable
by OCTA, and transient occlusive events are significantly more
frequent in the deep capillary bed of Ins2Akita compared to WT
mice.41 Deep retinal ischemia resulting from diminished
capillary perfusion at 6 months could explain why we found
significant vascular expansion at the 10.5-month endpoint,
since proliferative remodeling is the vascular response to
FIGURE 7. RGC and visual acuity loss. (A) RGC counts in retinal flat mounts immunolabeled with Brn3, compared across groups at the 10.5-month
endpoint. RGC counts of AAV2.REPORTER treated Ins2Akita retinas were significantly lower than all other groups. (B) Averaged ODþOS OptoMotry
scores of 10.5-month-old WT and Ins2Akita mice. All Ins2Akita mice showed significant loss of visual acuity compared to age-matched WT littermates
at 10.5 months. *P < 0.05, **P < 0.01, and ***P < 0.001, respectively.
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restore blood flow. Our future plans include longitudinal
studies to further examine the association between hypergly-
cemia, retinal blood flow, and Tie2 modulation in the aging
diabetic animal.
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